{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-058655","form_type":"8-K","ticker":"CVRX","cik":"0001235912","company_name":"CVRx, Inc.","filed_at":"2026-05-11T20:10:52+00:00","discovered_at":"2026-05-11T20:12:00.323223+00:00","generated_at":"2026-05-11T22:18:03.588399+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CVRx Q1 revenue $14.8M (+20% YoY); raises FY gross margin guidance","bullets":["U.S. revenue $13.7M (+22% YoY); active implanting centers grew to 257 from 227 a year ago.","Net loss $13.1M ($0.50 EPS) vs $13.8M ($0.53 EPS) in Q1 2025.","First site activated and first patient enrolled in BENEFIT-HF trial; could expand indicated population ~3x.","FY2026 guidance: revenue $63-67M; gross margin raised to 85-87% from prior 84-86%.","Cash $72.3M; Q2 2026 revenue expected $15.1-16.1M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-058655","json":"https://secwatch.observer/filing/0001104659-26-058655.json","markdown":"https://secwatch.observer/filing/0001104659-26-058655.md","text":"https://secwatch.observer/filing/0001104659-26-058655.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1235912/000110465926058655/0001104659-26-058655-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1235912/000110465926058655/tm2614163d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-11T22:18:03.588399+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e308640d00911873fe7b810fc5ddc616e6a8af68","claim":"CVRx, Inc. reported first quarter ended March 31, 2026 results: revenue $14.8 million, net income $13.1 million, or $0.50 per share, EPS $0.50 per share. Guidance reaffirmed.","evidence_excerpt":"cardiovascular diseases, today announced its financial and operating results for the first quarter of 2026. Recent Highlights · Total revenue for the first quarter of 2026 was $14.8 million, an increase of approximately 20% over the prior year quarter · U.S. revenue for the first quarter of 2026 was $13.7 million, an increase of 22% over the prior year quarter ·","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1235912/000110465926058655/0001104659-26-058655-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Revenue","value":"$14.8 million"},{"label":"Net income","value":"$13.1 million, or $0.50 per share"},{"label":"EPS","value":"$0.50 per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}